W. James Alexander

Dr. Alexander is an internist and infectious disease specialist. After obtaining his medical degree at the University of Mississippi, Dr. Alexander completed Internal Medicine training at the University of Alabama at Birmingham and a Fellowship in Infectious Diseases. After a decade as a Public Health Officer, Dr. Alexander joined the pharma industry and supervised US clinical development of antibacterials and antivirals at Beecham Laboratories. Dr. Alexander joined Glaxo in 1990 and played a key role in US Phase 3 clinical studies for the treatment of asthma. Subsequently, Glaxo chose Dr. Alexander as the international clinical leader for lamivudine as a treatment for HIV infection.

Dr. Alexander’s expertise was next recognized by his appointment as head of Glaxo (US) Pharmacovigilance in 1994 and, in 1996, he was named worldwide head of pharmacovigilance for GlaxoWellcome. After leaving GlaxoWellcome in 1998, he has worked with clinical research organizations (CROs) and has provided consulting services to pharmaceutical companies to advance clinical development programs in respiratory, neurology, infectious disease, and oncology indications.